Approaches to Optimizing Dantrolene Neuroprotection for the Treatment of Alzheimer's Disease.


Journal

Current Alzheimer research
ISSN: 1875-5828
Titre abrégé: Curr Alzheimer Res
Pays: United Arab Emirates
ID NLM: 101208441

Informations de publication

Date de publication:
2020
Historique:
received: 29 06 2019
revised: 24 02 2020
accepted: 11 05 2020
pubmed: 23 5 2020
medline: 5 8 2021
entrez: 23 5 2020
Statut: ppublish

Résumé

Alzheimer's Disease (AD), a neurodegenerative disorder with high incidence and mortality, is leading its way to the top of the list of the deadliest diseases without an effective disease-modifying drug. Ca2+ dysregulation, specifically abnormal release of Ca2+ via over activated ryanodine receptor (RyR), has been increasingly considered as an alternative upstream mechanism in AD pathology. Consequently, dantrolene, a RyR antagonist and FDA approved drug to treat malignant hyperthermia and chronic muscle spasms, has been shown to ameliorate memory loss in AD transgenic mice. However, the inefficiency of dantrolene to pass the Blood Brain Barrier (BBB) and penetrate the Central Nervous System needs to be resolved, considering its dose-dependent neuroprotection in AD and other neurodegenerative diseases. In this mini-review, we will discuss the current status of dantrolene neuroprotection in AD treatment and a strategy to maximize its beneficial effects, such as intranasal administration of dantrolene.

Identifiants

pubmed: 32442084
pii: CAR-EPUB-106843
doi: 10.2174/1567205017666200522204722
pmc: PMC7705762
mid: NIHMS1649301
doi:

Substances chimiques

Calcium Channel Blockers 0
Neuroprotective Agents 0
Ryanodine Receptor Calcium Release Channel 0
Dantrolene F64QU97QCR

Types de publication

Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

324-328

Subventions

Organisme : NIA NIH HHS
ID : R01 AG061447
Pays : United States

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Références

Neurocrit Care. 2009;10(1):103-15
pubmed: 18696266
Alzheimer Dis Assoc Disord. 2015 Jan-Mar;29(1):1-5
pubmed: 25551862
Expert Opin Pharmacother. 2009 Jul;10(10):1657-64
pubmed: 19527190
J Alzheimers Dis. 2013;35(4):777-88
pubmed: 23542865
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8850-5
pubmed: 11438712
Ann N Y Acad Sci. 1994 Dec 15;747:1-11
pubmed: 7847664
Nat Rev Neurol. 2019 Jul;15(7):365-366
pubmed: 31138932
Arch Neurol. 2012 Nov;69(11):1430-40
pubmed: 22892585
Trends Neurosci. 2008 Sep;31(9):454-63
pubmed: 18675468
J Neurosci. 2012 Aug 22;32(34):11820-34
pubmed: 22915123
J Intern Med. 2014 Mar;275(3):251-83
pubmed: 24605808
Biochim Biophys Acta Mol Cell Res. 2018 Nov;1865(11 Pt B):1745-1760
pubmed: 30059692
Neurosci Lett. 1993 Aug 6;158(1):105-8
pubmed: 8233063
J Vet Pharmacol Ther. 2014 Jun;37(3):286-94
pubmed: 24219828
Br J Clin Pharmacol. 2012 Apr;73(4):504-17
pubmed: 22035455
Pflugers Arch. 2010 Feb;459(3):441-9
pubmed: 19795132
N Engl J Med. 2013 Jul 25;369(4):341-50
pubmed: 23883379
BMC Neurosci. 2008 Dec 10;9 Suppl 3:S5
pubmed: 19091002
Neurosci Lett. 2012 May 16;516(2):274-9
pubmed: 22516463
Acta Neuropathol. 2017 Nov;134(5):749-767
pubmed: 28631094
J Alzheimers Dis Parkinsonism. 2017 Aug;7(5):
pubmed: 29214114
AAPS J. 2015 Jul;17(4):780-7
pubmed: 25801717
Dis Model Mech. 2011 Sep;4(5):634-48
pubmed: 21596710
J Alzheimers Dis. 2020;76(4):1375-1389
pubmed: 32623395
Int J Mol Sci. 2020 Feb 04;21(3):
pubmed: 32033164
PLoS One. 2012;7(12):e52056
pubmed: 23284867
Proc Natl Acad Sci U S A. 2017 May 2;114(18):4811-4815
pubmed: 28373535
J Neurosci. 2010 Jun 23;30(25):8566-80
pubmed: 20573903
Exp Neurol. 2008 Mar;210(1):109-17
pubmed: 18035355
Alzheimer Dis Assoc Disord. 2015 Jul-Sep;29(3):184-191
pubmed: 25650693
Biochem Pharmacol. 2013 Feb 1;85(3):289-305
pubmed: 23178653
Int J Alzheimers Dis. 2012;2012:369808
pubmed: 22506132
Neurobiol Aging. 2011 Dec;32(12):2321.e1-12
pubmed: 20579773
Anaesthesia. 2004 Apr;59(4):364-73
pubmed: 15023108
PLoS One. 2020 Mar 11;15(3):e0229156
pubmed: 32160210

Auteurs

Matan B Abou (MB)

Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States.

Liang Sun (L)

Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States.
Department of Anesthesiology, Peking University People's Hospital, Beijing 100044, China.

Huafeng Wei (H)

Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH